Can an aging nerve cell recover what it has lost?
ER-100 reaches an early human milestone. The promise—and the limits—belong together.
Sight is not an abstract longevity outcome. It is a face across a room, a sentence on a page, a way of moving through the world. That is why an experiment aimed at recovering optic-nerve function deserves attention even before anyone knows whether it will work.
ER-100 is an investigational gene therapy built around a different question from simply replacing damaged cells: can changing aspects of a cell’s gene-expression program help it function better? Its registered first-in-human study concerns optic neuropathies, not whole-body age reversal.
What has actually been reported
In an October 8 announcement, Life Biosciences described the first three participants with open-angle glaucoma. The company reported no serious adverse events or dose-limiting toxicities through day 56. It also described preliminary visual-field improvements in two participants. These are sponsor-reported observations, not independently adjudicated efficacy findings.
The registry describes a nonrandomized, open-label phase 1 study, with safety central to its design and follow-up planned for up to five years. A registration describes the experiment; it does not certify its outcome. No results were posted in the registry record retrieved for this review.
Why the mechanism is interesting
ER-100 delivers instructions for OCT4, SOX2 and KLF4—together called OSK—with expression controlled by doxycycline. This is an attempt to alter cellular state, rather than the same procedure as editing a disease-causing DNA variant or transplanting a new population of cells. Those distinctions matter when different technologies are all described as “rejuvenation.”
The treatment, its delivery procedure and the accompanying medicines form one clinical intervention. They cannot be taken apart and repurposed into a do-it-yourself protocol. The meaningful question is whether the complete, controlled approach produces durable visual benefit with acceptable harm.
What three participants cannot settle
Visual-field measurements fluctuate. An uncontrolled study cannot determine how much of an observed change is attributable to treatment, repeat testing or other influences. Eight weeks without a serious event in three people does not establish long-term safety, and improvement in an early measurement is not equivalent to restored sight.
For the next stage, I would look for reproducibility across participants, transparent reporting of adverse events, sustained function, and eventually comparisons capable of testing efficacy. A decision to continue dose escalation is a decision about the next experiment, not an approval for routine care.
The opportunity remains extraordinary without enlarging the result. A biological idea is now being asked a human question. The task is to keep that question open long enough—and test it carefully enough—to learn whether it can help someone see.
Sources and evidence
Life Biosciences: interim ER-100 Phase 1 observations
October 8, 2026 · Sponsor announcement; three participants
ER-100 registered Phase 1 study, NCT07290244
Registry last update May 19, 2026; checked October 25 · Sponsor-submitted trial registration; no posted results